Maxim Group Reiterates “Hold” Rating for NovaBay Pharma (NBY)
NovaBay Pharma (NYSE:NBY) opened at 3.74 on Tuesday. The company’s market cap is $42.08 million. NovaBay Pharma has a 12-month low of $1.75 and a 12-month high of $9.50. The firm’s 50 day moving average is $3.27 and its 200 day moving average is $2.60.
NovaBay Pharma (NYSE:NBY) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.06. The firm had revenue of $2.70 million for the quarter, compared to analyst estimates of $1.76 million. Equities research analysts anticipate that NovaBay Pharma will post ($1.77) EPS for the current fiscal year.
NovaBay Pharma Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
Receive News & Ratings for NovaBay Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharma and related companies with MarketBeat.com's FREE daily email newsletter.